SND-002

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameSND-002
Drug Alias NameSND-002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Source of cells > Sentinel lymph node-derived
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursColorectal NeoplasmsMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEUMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesJiangsu Sinorda Biomedicine Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesGuizhou Shengnuo Biological Technology Co LtdAnhui Shengnuo Pharmaceutical Technology Co LtdJiangsu Sinorda Biomedicine Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursColorectal NeoplasmsMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A